Clinical trial NCT04655989: A Study to Demonstrate the Safety and Effectiveness of the NIKKISO DBB-EXA ES Hemodialysis Delivery System
Official title: A Prospective, Multi-Center, Randomized, Controlled Trial to Demonstrate the Safety and Effectiveness of the NIKKISO DBB-EXA ES Hemodialysis Delivery System in Adult Patients With Chronic Renal Failure
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Dialysis
Chronic Renal Failure
Lead sponsor: Nikkiso America, Inc.
Sponsor class: INDUSTRY
Collaborators: name: NAMSA
First posted: 2020-12-07
Enrollment: 31
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Intervention model description: Group A subjects will be assigned to 4 weeks of routine dialysis (control group) followed by 4 weeks of treatment dialysis with the DBB-EXA ES Hemodialysis System (investigational group).

Group B subjects will be assigned to 4 weeks of treatment dialysis with the DBB-EXA ES Hemodialysis System (investigational group) followed by 4 weeks of routine dialysis (control group).

After completion of the initial 8-week treatment period, subjects were eligible for the Vascular Access Recirculation Rate Measurement (VARRM) sub-study.
Primary purpose: TREATMENT

Brief summary: The study objective is to verify the safety and effectiveness of the DBB-EXA ES Hemodialysis Delivery System to consistently deliver dialysate of the appropriate quality for infusion.

Detailed description: The study objective is to verify the safety and effectiveness of the DBB-EXA ES Hemodialysis Delivery System to consistently deliver dialysate of the appropriate quality for infusion. The safety will be evaluated by comparing the adverse event rate in the DBB-EXA ES Hemodialysis group (investigational) vs. the standard dialysis group (control).

The study population will include eligible adult patients diagnosed with chronic renal failure requiring routine dialysis treatments for a minimum of 90 days and with a minimum of 3 weekly sessions. Treatment duration will be at the discretion of the investigator. The duration of study participation for each subject is approximately eight (8) weeks; four (4) weeks of routine dialysis and four (4) weeks of treatment dialysis. The expected total study duration across all subjects (from recruitment to last subject visits) is approximately five (5) to six (6) months, dependent upon subject recruitment/enrollment and meeting 360 evaluable treatments. A minimum of 30 eligible subjects will be enrolled into the study ensuring a minimum of 360 evaluable treatments in the treatment arm.

The sub-study, VARRM, was conducted following the subject's completion of the primary eight (8) week clinical study. The total participation time for the VARRM sub-study was approximately 1.5 weeks. Subjects that participated in the VARRM sub-study had their vascular recirculation rates collected during treatments. A minimum of 12 subjects were expected to participate in this sub-study, with a minimum of 21 and maximum of 36 dialysis accesses evaluated.

Eligibility criteria: Inclusion Criteria:

1. Male or female ≥18 years of age
2. Chronic renal failure diagnosis
3. Minimum of 90 days of stable hemodialysis treatment with a minimum of 3 treatment sessions per week. The duration of each treatment session is in the discretion of the investigator.
4. Reliable vascular access
5. Hemodialysis treatment a minimum of three (3) sessions per week
6. Subject agrees not to eat or drink during treatments
7. Understand and sign the informed consent form

Exclusion Criteria:

1. Unable to receive anticoagulation
2. Hypercoagulation diagnosis
3. Hyperviscosity diagnosis
4. Most recent hemoglobin less than 9
5. Active bacterial infection
6. Women of childbearing potential, pregnant and/or lactating females verified by urine or serum pregnancy test
7. Life expectancy less than 6 months
8. Cognitive impairment, dementia, or other condition that limits the ability to provide informed consent and to comply with study procedures, or any other reason that the Investigator believes to contraindicate study participation.
9. Current or known future need for a central venous catheter (CVC)
10. Involved in another clinical research trial within the prior 30 days
11. Diagnosed with systemic consistent hypotension as defined by being systolic \<90 mm Hg or diastolic \<60 mm Hg
12. Immunocompromised patients (e.g. active malignancy, current chemotherapy treatment, transplant recipients, any patient on immunosuppressive medication, or patients with current autoimmune disease).

Primary outcomes:
measure: Adverse Event Rate
timeFrame: 8 weeks
Secondary outcomes:
measure: Total Colony Forming Units and Endotoxin Levels
timeFrame: 8 Weeks
measure: Fluid Balance Evaluation
timeFrame: 8 Weeks
Other outcomes:
measure: Sub-Study VARRM
timeFrame: 1.5 weeks
Locations:
city: Detroit
country: United States
facility: Great Lakes Dialysis
state: Michigan
city: Southfield
country: United States
facility: Great Lakes Dialysis - West
state: Michigan
Study officials:
References: